The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
Lattice degeneration of the retina occurs when your retina gets thinner over time. About 10% of people experience this condition within their lifetime. It does not directly cause vision issues, but ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Risk factors for rhegmatogenous retinal detachment following cataract surgery include younger age, ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
ANN ARBOR, Mich., April 12, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal ...
Eileen Hwang, MD, PhD, joined the John A. Moran Eye Center in October 2019. She specializes in the medical and surgical treatment of children and adults with retinal conditions. This includes ...
Researchers found a strong link between increased exposure to air pollution and ocular complications, with increased exposure to nitrogen oxides (NOx) and particulate matter with diameter less than 10 ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback